LONDON (Alliance News) - Life sciences company ValiRx PLC on Thursay said its ValiSeek Ltd joint venture with Tangent Reprofiling Ltd has initiated the process for a late stage clinical trial of its VAL401 lung cancer drug.
A clinical trial contract has been signed between ValiSeek and Clinical Accelerator, a UK-based clinical trial management organisation, to handle the phase 2b clinical trial in patients with non-small-cell lung adenocarcinoma.
"As the second ValiRx product to enter the clinical trial process, I look forward to seeing the potential of the VAL401 project being crystallised through the collection of a first set of real world patient data," said Satu Vainikka, ValiRx's chief executive.
Shares in ValiRx were down 1.1% to 35.62 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)